CALC

Rating neutralAI Memo

CalciMedica

As of 2026-04-15/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Nasdaq compliance deadlines in September 2026 • 2026-09-14

Expected move: -45%

Biggest risk

The bear case is more immediate: CALC has already lost its AKI readout momentum, now faces two Nasdaq compliance clocks, and still appears likely to need additional capital before long unless AP progress becomes concrete [#8-K-2026-03-18][#10-K-2026-03-03].

Invalidation

Break below $0 or thesis failure.

What would change my mind?

The remaining long thesis is that KOURAGE's stoppage does not kill the platform: management says its review found no drug-related toxicity, AP remains active with a possible pivotal path in 1H 2026, and even modest regulatory progress could re-rate a sub-$100 million market cap sharply [#PR-2026-01-28][#PR-2026-03-03].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-04-15

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Runway and financing posture become more visible
Auxora acute pancreatitis pivotal-program design
The remaining long thesis is that KOURAGE's stoppage does not kill the platform: management says its review found no drug-related toxicity, AP remains active with a possible pivotal path in 1H 2026, and even modest regulatory progress could re-rate a sub-$100 million market cap sharply [#PR-2026-01-28][#PR-2026-03-03].

BearKey bullets

Acute pancreatitis pivotal-program design may slip or fail to produce a commercially credible regulatory path.
Additional financing could be dilutive or come with restrictive terms.
Failure to regain Nasdaq compliance by the September 2026 deadlines could trigger delisting procedures.

WatchKey bullets

Nasdaq compliance deadlines in September 2026

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $0 (p=45%)

Bull/Bear spread: +71% / -85%

Vs latest close: Bull +71% · Base -45% · Bear -85%

Scenario probabilities

Bull Target: $1 (p=25%)Base Target: $0 (p=45%)Bear Target: $0 (p=30%)

Commentary

Sentiment remains fragile and mostly monitoring-driven. The January 28, 2026 KOURAGE discontinuation reset the story negatively even though management later said its review found no drug-related toxicity and plans FDA discussions in AKI [#PR-2026-01-28][#PR-2026-03-03]. Since then, the more concrete near-term disclosures have been about Nasdaq noncompliance and finite runway, which leaves the stock trading as an event-risk and financing-risk vehicle rather than a clean clinical-upside setup [#8-K-2026-03-18][#10-K-2026-03-03].

As of 2026-04-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Runway and financing posture become more visible
Auxora acute pancreatitis pivotal-program design

Scenarios

Bull Target (Scenario probability)

$1 / p=25% prob

Base Target (Scenario probability)

$0 / p=45% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Price $1 as of 2026-05-29

Nearest Scenario: Base (∆ 45%)

Targets vs latest close: Bull +71% · Base -45% · Bear -85%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-09-14
Nasdaq compliance deadlines in September 2026
CalciMedica disclosed notices for both market-value and minimum-bid-price noncompliance, with cure deadlines of September 9, 2026 and September 14, 2026, respectively; failure to cure could move the stock toward delisting, while a cure or approved remediation plan would remove a major overhang [#8-K-2026-03-18].
Prob 70.00% • Move -30.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Runway and financing posture become more visible
2026-08-31
The company reported $13.0 million of cash, cash equivalents, and short-term investments at December 31, 2025 and guided runway into the fourth quarter of 2026; absent a strong clinical/regulatory win, investors are likely to focus on financing, balance-sheet repair, or capital-structure actions over the next several quarters [#10-K-2026-03-03][#PR-2026-03-03].
Prob 65% • Move -20% • Priced-in 45%

Long-term Catalysts

Months to a year

Auxora acute pancreatitis pivotal-program design
2026-06-30
Management said it expects to finalize the pivotal-program design for Auxora in acute pancreatitis in the first half of 2026 after constructive FDA engagement; a concrete protocol or regulatory path would be the clearest fundamental re-rating lever left after the KOURAGE setback [#PR-2026-03-03].
Prob 55% • Move 90% • Priced-in 20%

Risks

Acute pancreatitis pivotal-program design may slip or fail to produce a commercially credible regulatory path.
Additional financing could be dilutive or come with restrictive terms.
Failure to regain Nasdaq compliance by the September 2026 deadlines could trigger delisting procedures.
Low-float micro-cap biotech trading can remain disconnected from fundamental updates for extended periods.
The discontinued KOURAGE study may still limit confidence in Auxora's broader development path even if no drug-related toxicity is identified.

Peers

Symbol	Summary
SPRB	Loose small-cap clinical-biotech comp with heavy dependence on single-program milestones and financing access rather than commercial execution.
OKYO	Another micro-cap development-stage biotech where valuation is dominated by event timing, listing compliance, and capital-markets optionality more than near-term revenue.
IPSC	Clinical-stage peer by market cap that helps frame how quickly sentiment can swing on protocol, trial, and financing updates, though the pipeline is not directly comparable.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-04-15

Loading AI feed…

Symbol

Summary

SPRB

Loose small-cap clinical-biotech comp with heavy dependence on single-program milestones and financing access rather than commercial execution.

OKYO

Another micro-cap development-stage biotech where valuation is dominated by event timing, listing compliance, and capital-markets optionality more than near-term revenue.

IPSC

Clinical-stage peer by market cap that helps frame how quickly sentiment can swing on protocol, trial, and financing updates, though the pipeline is not directly comparable.